Axol Bioscience offers cardiomyocytes that are extracted only from human iPSCs. The company does not utilize any embryonic stem cells (ESCs) or animal cells.
Axol Bioscience provides quality cells that deliver consistent results. It is a brand that users can trust.
Human iPSC-derived atrial cardiomyocytes from Axol Bioscience contain one million cells per vial.
The atrial-specific markers atrial natriuretic peptide (ANP) and atrial myosin light chain 2 (MLC2a) are expressed by Axol iPSC-derived atrial cardiomyocytes. Atrial cardiomyocytes are crucial for studying atrial fibrillation like irregular heart rate; hence, they are highly suitable for disease modeling.
Axol Bioscience’s iPSC-derived atrial cardiomyocytes have been extracted from the same newborn male donor as the company’s iPSC-derived ventricular cardiomyocytes that are highly validated.
Axol iPSC-derived cardiomyocytes and serum-free, fully defined cardiomyocyte maintenance medium provide scientists with a complete range of complementary culture reagents and cell types for cardiotoxicity testing and disease modeling.
||Cord blood CD34+ cells
|Donor age at sampling
||A29 A68, B38(Bw4) B44(Bw4), Cw8 Cw12
||Monolayer & chemically defined medium
||1 million cells
||vapour phase nitrogen